<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glofitamab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glofitamab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glofitamab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141820" href="/d/html/141820.html" rel="external">see "Glofitamab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58315674"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cytokine release syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving glofitamab. Premedicate before each dose, and initiate treatment with the glofitamab step-up dosing schedule to reduce the risk of CRS. Withhold glofitamab until CRS resolves or permanently discontinue based on severity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58441045"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Columvi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58085445"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Columvi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58315677"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD20;</li>
<li>
                        Antineoplastic Agent, Anti-CD3;</li>
<li>
                        Antineoplastic Agent, Bispecific T Cell Engager;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F58348719"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Ensure patients are well-hydrated prior to glofitamab administration. Avoid administering glofitamab to patients with active infection. Should only be administered by a qualified provider with appropriate medical support to manage severe cytokine release syndrome (CRS). The manufacturer recommends hospitalization during infusion and for 24 hours following completion of step-up dose 1 (2.5 mg on day 8 of cycle 1). Patients who experienced CRS (any grade) during step-up dose 1 should be hospitalized during infusion and for 24 hours following completion of step-up dose 2 (10 mg on day 15 of cycle 1). CRS may occur with step-up dose 2 in patients who did not experience CRS with step-up dose 1. Patients who experienced ≥ grade 2 CRS with the previous infusion should be hospitalized during infusion and for 24 hours following completion of the next glofitamab infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication: </i>Premedicate prior to each glofitamab dose. See "Glofitamab Recommended Premedications" table.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prophylaxis:</i> Administer antimicrobial prophylaxis according to guidelines. Consider prophylaxis for <i>pneumocystis jirovecii</i> pneumonia prior to initiating glofitamab. Consider initiating herpes virus prophylaxis prior to initiating glofitamab to prevent herpes zoster reactivation. Consider prophylaxis for cytomegalovirus infection (in patients at increased risk). Administer antihyperuricemics and ensure adequate hydration in patients at risk for tumor lysis syndrome. <b></b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48925eaf-0a5b-4db7-8ad8-85a7a9637b97">Diffuse large B-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, relapsed or refractory: IV: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer pretreatment with a single obinutuzumab dose on cycle 1, day 1 (7 days prior to the first glofitamab dose) to deplete B cells (circulating and lymphoid tissue).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Glofitamab IV Dosing Schedule<sup>a, b</sup> (21-day treatment cycles)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Cycle number</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Day of treatment</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Glofitamab dose<sup>b </sup>and infusion duration</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Continue for a maximum of 12 cycles (including cycle 1 step-up dosing) or until disease progression or unacceptable toxicity (whichever occurs first).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Manufacturer’s labeling, Dickinson 2022.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Refer to obinutuzumab monograph for dosing.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> May extend the infusion duration up to 8 hours if cytokine release syndrome (CRS) was experienced with the previous glofitamab dose.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e</sup> Maintain an infusion duration of 4 hours if CRS was experienced with the previous glofitamab dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cycle 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Day 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer obinutuzumab<sup>c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Day 8</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2.5 mg (step-up dose 1) over 4 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Day 15</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 mg (step-up dose 2) over 4 hours<sup>d</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cycle 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Day 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg over 4 hours<sup>d</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cycles 3 to 12<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Day 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 mg over 2 hours<sup>e</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Glofitamab Recommended Premedications</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Cycle/Treatment day</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Patients requiring premedication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Premedication</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Administration schedule</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>If dexamethasone is not available, may use prednisone 100 mg, prednisolone 100 mg, or methylprednisolone 80 mg IV.</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> CRS = cytokine release syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cycle 1 (days 8 and 15); cycle 2; cycle 3</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">All patients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dexamethasone 20 mg IV<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete at least 1 hour prior to glofitamab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acetaminophen 500 to 1,000 mg orally</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">At least 30 minutes prior to glofitamab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Antihistamine (diphenhydramine 50 mg orally or IV or equivalent)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete at least 30 minutes prior to glofitamab infusion.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">All subsequent infusions</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">All patients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acetaminophen 500 to 1,000 mg orally</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">At least 30 minutes prior to glofitamab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Antihistamine (diphenhydramine 50 mg orally or IV or equivalent)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete at least 30 minutes prior to glofitamab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients who experienced CRS<sup>b</sup> (any grade) with the previous dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dexamethasone 20 mg IV<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete at least 1 hour prior to glofitamab infusion.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed </i>
<i>or delayed doses: </i>If a glofitamab dose is missed or delayed, restart based on the table.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommendations for Restarting Glofitamab IV After a Dosing Delay</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Last dose administered</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Time since last dose</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Action for next glofitamab dose(s)<sup>a</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Administer premedications prior to glofitamab dose and monitor appropriately.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Patients should be hospitalized during and for 24 hours after the glofitamab 2.5 mg dose.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Patients should be hospitalized during and for 24 hours after the glofitamab 10 mg dose if cytokine release syndrome (any grade) occurred with the most recent glofitamab 2.5 mg dose.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 1 (obinutuzumab)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer glofitamab 2.5 mg (cycle 1 day 8)<sup>b</sup> then resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat obinutuzumab pretreatment dose, then administer glofitamab 2.5 mg (cycle 1 day 8)<sup>b</sup> and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 8 (glofitamab 2.5 mg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer glofitamab 10 mg (cycle 1 day 15)<sup>c</sup> then resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;2 to ≤4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat glofitamab 2.5 mg (cycle 1 day 8),<sup>b</sup> then administer glofitamab 10 mg (cycle 1 day 15)<sup>c</sup> and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat obinutuzumab pretreatment dose and glofitamab 2.5 mg (cycle 1 day 8),<sup>b</sup> then administer glofitamab 10 mg (cycle 1 day 15)<sup>c</sup> and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 15 (glofitamab 10 mg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer glofitamab 30 mg (cycle 2 day 1) then resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;2 to ≤6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat glofitamab 10 mg (cycle 1 day 15),<sup>c</sup> then administer glofitamab 30 mg (cycle 2 day 1) and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat obinutuzumab pretreatment dose, glofitamab 2.5 mg (cycle 1 day 8),<sup>b</sup> and glofitamab 10 mg (cycle 1 day 15),<sup>c</sup> then administer glofitamab 30 mg (cycle 2 day 1) and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cycle 2 and beyond (glofitamab 30 mg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Administer glofitamab 30 mg and resume the planned treatment schedule.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">&gt;6 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Repeat cycle 1 regimen (obinutuzumab day 1, glofitamab 2.5 mg day 8,<sup>b</sup> glofitamab 10 mg day 15<sup>c</sup>), then administer glofitamab 30 mg (day 1 of the next cycle) and resume the planned treatment schedule.</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58348742"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney function estimated using the Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to &lt;90 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, no clinically significant difference in glofitamab pharmacokinetics was observed based on CrCl 30 to &lt;90 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (effects on glofitamab pharmacokinetics are unknown).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage kidney disease (CrCl &lt;15 mL/minute): There are no dosage adjustments provided in the manufacturer’s labeling (effects on glofitamab pharmacokinetics are unknown).</p></div>
<div class="block doha drugH1Div" id="F58348743"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN): There are no dosage adjustments provided in the manufacturer’s labeling; however, no clinically significant difference in glofitamab pharmacokinetics was observed based on mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer’s labeling (effects on glofitamab pharmacokinetics are unknown).</p></div>
<div class="block doo drugH1Div" id="F58348744"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American</i>
<i> Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2</sup> experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F58348745"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to "Dosing: Adult" for recommendations on restarting glofitamab after dose delays.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytokine release syndrome:</b> If cytokine release syndrome (CRS) is suspected, interrupt glofitamab until CRS resolves; manage according to the table below and per clinical practice guidelines. Identify CRS based on the clinical presentation. Evaluate for other causes of fever, hypotension, and hypoxia, and manage appropriately. Supportive therapy for CRS may include intensive care for severe or life-threatening CRS.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Glofitamab-Related CRS Management<sup>d</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>CRS grade</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Presenting symptoms</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Fever may be masked by premedications; if clinical presentation is consistent with CRS, follow CRS management recommendations.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Infusion duration may be extended up to 8 hours (as appropriate) for that cycle.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Refer to "Dosing: Adult" for recommendations for restarting glofitamab after a dosing delay.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>CRS = cytokine release syndrome; CPAP = continuous positive airway pressure; BiPAP = bilevel positive airway pressure.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F),<sup>a</sup> attributed to CRS.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab and manage per practice guidelines. If symptoms resolve, restart infusion at a slower rate.<sup>b</sup></p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved for at least 72 hours prior to the next glofitamab dose.<sup>c</sup></p>
<p style="text-indent:0em;text-align:left;">Consider a slower infusion rate for the next dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a </sup>with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension not requiring vasopressors</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring low-flow oxygen (&lt;6 L/minute) via nasal cannula or blow-by.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab and manage per practice guidelines. If symptoms resolve, restart infusion at a slower rate.<sup>b</sup></p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved for at least 72 hours prior to the next glofitamab dose.<sup>c</sup></p>
<p style="text-indent:0em;text-align:left;">For the next dose, consider a slower infusion rate, monitor more frequently, and consider hospitalization.</p>
<p style="text-indent:0em;text-align:left;">For recurrent grade 2 CRS, manage per grade 3 CRS.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring a vasopressor (with or without vasopressin)</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring high-flow oxygen (≥6 L/minute) via nasal cannula, face mask, non-rebreather mask, or Venturi mask.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab and manage per practice guidelines, which may include intensive care.</p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved for at least 72 hours prior to the next glofitamab dose.<sup>c</sup></p>
<p style="text-indent:0em;text-align:left;">Hospitalize for the next glofitamab dose, monitor more frequently, and consider a slower infusion rate.<sup>b</sup></p>
<p style="text-indent:0em;text-align:left;">For recurrent grade 3 CRS, permanently discontinue glofitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring multiple vasopressors (excluding vasopressin)</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring oxygen via positive pressure (eg, CPAP, BiPAP,<sup>d</sup> intubation, and mechanical ventilation).</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue glofitamab.</p>
<p style="text-indent:0em;text-align:left;">Manage CRS per practice guidelines and provide supportive therapy, which may include intensive care.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurologic toxicity: </b>At the first sign of neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), consider withholding glofitamab and obtaining a neurology evaluation (based on the type and severity of neurotoxicity). Rule out other causes of neurologic symptoms. Provide supportive care (which may include intensive care).</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Glofitamab-Related Neurologic Toxicity Management (Including ICANS<sup>e</sup>)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Based on the American Society of Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Consider the type of neurotoxicity prior to deciding to withhold glofitamab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Refer to "Dosing: Adult" for recommendations for restarting glofitamab after a dosing delay.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> Evaluate risks versus benefits prior to resuming glofitamab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>ICANS = immune effector cell-associated neurotoxicity syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">Neurologic toxicity (including ICANS<sup>a</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Continue glofitamab and monitor neurologic toxicity symptoms.</p>
<p style="text-indent:0em;text-align:left;">If ICANS, manage per practice guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until neurologic toxicity symptoms improve to grade 1 or baseline.<sup>b, c</sup></p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy and consider neurologic evaluation.</p>
<p style="text-indent:0em;text-align:left;">If ICANS, manage per practice guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until neurologic toxicity symptoms improve to grade 1 or baseline for at least 7 days.<sup>c, d</sup></p>
<p style="text-indent:0em;text-align:left;">For grade 3 neurologic events lasting &gt;7 days, consider permanently discontinuing glofitamab.</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy and consider neurology evaluation.</p>
<p style="text-indent:0em;text-align:left;">If ICANS, manage per practice guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue glofitamab.</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy, which may include intensive care; consider neurology evaluation.</p>
<p style="text-indent:0em;text-align:left;">If ICANS, manage per practice guidelines.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Recommended Glofitamab Dosage Modifications for Other Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Refer to "Dosing: Adult" for recommendations for restarting glofitamab after a dosing delay.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until ANC is ≥500/mm<sup>3</sup>.<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until platelets are ≥50,000/mm<sup>3</sup>.<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Infections</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 1 to 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab or consider permanently discontinuing based on severity. Manage infection appropriately and as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Withhold glofitamab in patients with active infection until infection resolves.<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">For grade 4 infection, consider permanently discontinuing glofitamab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tumor flare</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grades 2 to 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monitor for signs/symptoms of compression or obstruction due to mass effect secondary to tumor flare. Institute appropriate management, including antihistamines and corticosteroids.</p>
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until tumor flare resolves.<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or higher</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold glofitamab until adverse reaction resolves to grade 1 or baseline.<sup>a</sup></p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58348741"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58332831"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (48%), decreased serum phosphate (69%), decreased serum potassium (32%), decreased serum sodium (49%), hypouricemia (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (14%), diarrhea (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (72%; grades 3/4: 8%), decreased neutrophils (56%; grades 3/4: 26%), decreased platelet count (56%; grades 3/4: 8%), decreased serum fibrinogen (84%; grades 3/4: 21%), lymphocytopenia (90%; grades 3/4: 83%), tumor flare (12%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (70%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Serious infection (16%; including sepsis [4%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10%), gastrointestinal hemorrhage, nausea (10%), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (3%), tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reactions</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurotoxicity (dizziness [≤7%], headache [10%], immune effector cell-associated neurotoxicity [ICANS] [5%], mental status changes [cognitive dysfunction, confusion, delirium, disorientation, drowsiness: 5%], peripheral neuropathy [8%], vertigo [≤7%]), tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia, upper respiratory tract infection</p></div>
<div class="block coi drugH1Div" id="F58315680"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58348686"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cytokine release syndrome: Glofitamab may cause serious and fatal cytokine release syndrome (CRS). CRS occurred commonly in the clinical trial, with grade 1 CRS developing in over ½ of all patients, grade 2 in 14%, grade 3 in ~3%, and grade 4 in ~1% of patients. The most common manifestations of CRS included fever, tachycardia, hypotension, chills, and hypoxia. CRS occurred after the 2.5 mg glofitamab dose in over ½ of the patients, after the 10 mg dose in ~<sup>1</sup>/<sub>3</sub> of patients, in ~<sup>1</sup>/<sub>3</sub> of patients with the initial 30 mg dose, and with subsequent doses in a small percentage of patients. With the first step-up dose, the median time to onset of CRS (from the start of infusion) was 14 hours (range: 5 to 74 hours). CRS after any dose resolved in most cases, with a median duration of 2 days (range: 1 to 14 days). Recurrent CRS occurred in ~<sup>1</sup>/<sub>3</sub> of all patients. In patients where CRS first occurred with the 10 mg dose, events were predominantly grade 1, but cases of grades 2 and 3 also occurred. Glofitamab should be administered in a facility equipped to monitor and manage CRS and should be initiated according to the step-up dosing schedule to reduce the risk of CRS. Administer pretreatment medications and ensure adequate hydration. The initial dose requires hospitalization; the second step-up dose and subsequent doses may also require hospitalization (if ≥ grade 2 CRS occurred with the prior dose).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Glofitamab may cause serious or fatal infections; grade 3 and 4 infections (including COVID-19 infections) were observed. COVID-19 infections included pneumonia and sepsis. Neutropenic fever was also reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic toxicity: Glofitamab may cause serious and fatal neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS). The most frequent neurologic toxicities of any grade were headache, peripheral neuropathy, dizziness/vertigo, and mental status changes (including confusion, cognitive disorder, disorientation, somnolence, and delirium). Grade 3 or higher neurologic adverse reactions included somnolence, delirium, and myelitis and occurred in a small percentage of patients. Cases of ICANS (any grade) occurred in ~5% of patients. The risk of neurologic toxicity may be increased if glofitamab is administered with other products that also cause dizziness or mental status changes. Optimize concurrent medications and hydration to avoid dizziness or mental status changes. Institute appropriate fall precautions. Patients who are affected should refrain from driving and/or engaging in hazardous occupations or activities, such as operating heavy/potentially dangerous machinery until the neurologic toxicity fully resolves.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor flare: Glofitamab may cause serious tumor flare; grade 2 and 3 events have been reported. Tumor flare manifestations include localized pain and swelling at the sites of the lymphoma lesions and/or dyspnea from new pleural effusions. Cases of recurrent tumor flare have occurred. Most tumor flare events occurred during cycle 1, with a median time to first onset of 2 days (range: 1 to 16 days) after the first glofitamab dose; the median duration was 3.5 days (range: 1 to 35 days).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Patients ≥65 years of age experienced a higher rate of fatal adverse reactions (primarily from COVID-19 infections), compared to patients &lt;65 years of age.</p></div>
<div class="block foc drugH1Div" id="F58441046"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Columvi: Glofitamab-gxbm 10 mg/10 mL (1 mg/mL) (10 mL); Glofitamab-gxbm 2.5 mg/2.5 mL (1 mg/mL) (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F58085443"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58481993"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Columvi Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/2.5 mL (per mL): $1,226.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $1,226.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58085446"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Columvi: Glofitamab-gxbm 10 mg/10 mL (1 mg/mL) (10 mL); Glofitamab-gxbm 2.5 mg/2.5 mL (1 mg/mL) (2.5 mL)</p></div>
<div class="block accres drugH1Div" id="F58348769"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Glofitamab is available through specialty distributors and wholesalers. Distribution information is available at https://www.genentech-access.com/hcp/brands/columvi/learn-about-our-services/product-distribution.html or at 1-877-436-3683.</p></div>
<div class="block adm drugH1Div" id="F58348755"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse cycles 1 and 2 over 4 hours; may begin infusing over 2 hours in cycle 3 in the absence of cytokine release syndrome (CRS). Infusion time may need to be extended up to 8 hours if CRS was experienced with the prior dose. Administer via a dedicated line with a 0.2 micron in-line filter. Glofitamab should be administered by a health care provider with immediate access to appropriate medical support, including supportive medications for managing CRS.</p>
<p style="text-indent:-2em;margin-left:2em;">No incompatibilities have been observed with infusion sets with product-contacting surfaces of polyurethane (PUR), polyvinyl chloride, or polyethylene, and in-line filter membranes composed of polyether sulfone or polysulfone.</p></div>
<div class="block meg drugH1Div" id="F58348602"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761309s000lbl.pdf%23page%3D19&amp;token=zn6tFcWX3d1LKVneWGtHYccWeFiJUTqhl4Y9boEZ6AeoJZ%2BdcdrxfA4KQoDOGGpd6cLcv%2BdO6s8cJ53Ws59epP0QJGan751QX9MIvQhd41LqtuVlYcFElXAqvl8A%2BjYH&amp;TOPIC_ID=141793" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F58315679"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diffuse large B-cell lymphoma, relapsed or refractory:</b> Treatment of relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma in adults after 2 or more lines of systemic therapy.</p></div>
<div class="block mst drugH1Div" id="F58348601"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Glofitamab may be confused with epcoritamab, naxitamab, tafasitamab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58065097"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58065094"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of anti-CD20 B-cell depleting therapy is reduced. Anti-CD20 B-Cell Depleting Therapies may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Administer COVID-19 vaccine 2 to 4 weeks prior to the next scheduled dose of anti-CD20 therapy, if used chronically for the treatment of autoimmune disease. Revaccinate 6 months after completion of anti-CD20 therapy if used over a limited period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Glofitamab may increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58348643"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation. Patients who could become pregnant should use effective contraception during therapy and for 1 month after the last glofitamab dose.</p></div>
<div class="block pri drugH1Div" id="F58348644"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Glofitamab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Animal reproduction studies have not been conducted. Based on the mechanism of action, in utero exposure to glofitamab may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F58348645"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if glofitamab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer during therapy and for 1 month after the last glofitamab dose.</p></div>
<div class="block mop drugH1Div" id="F58348758"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood counts. Verify pregnancy status prior to treatment (in patients who could become pregnant). Monitor for signs/symptoms of cytokine release syndrome (CRS); at the first sign of CRS, immediately evaluate patients for hospitalization. Monitor for signs/symptoms of neurologic toxicity; promptly evaluate patients who experience neurologic toxicity (eg, tremors, dizziness, or adverse reactions that may impair cognition or consciousness), including potential neurology evaluation. Monitor for infections (before and during glofitamab treatment). Monitor for tumor flare; patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy; monitor for signs/symptoms of compression or obstruction due to mass effect secondary to tumor flare. Assess risk for and monitor for signs/symptoms of tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F58348697"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Glofitamab is a bispecific T-cell engaging antibody that targets CD3 and CD20; a novel 2:1 tumor–T-cell binding configuration confers bivalency for CD20 and monovalency for CD3 (Dickinson 2022). Glofitamab binds to CD20 expressed on the surface of B-cells and to the CD3 receptor expressed on T-cell surfaces, resulting in T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.</p></div>
<div class="block phk drugH1Div" id="F58348698"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Circulating B cells decreased to undetectable levels by cycle 1, day 10 (following obinutuzumab pretreatment and step-up glofitamab dose 1) in a majority of patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 7.6 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.617 L/day (at steady state).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Genentech.1">
<a name="Genentech.1"></a>Columvi (Glofitamab) [prescribing information]. South San Francisco, CA: Genentech Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507690">
<a name="36507690"></a>Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/36507690/pubmed" id="36507690" target="_blank">36507690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update.<i> J Clin Oncol.</i> 2021:39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glofitamab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141793 Version 16.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
